Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cdiffense: C. difficile Toxoid Vaccine in Adults at Risk for CDI
NCT01887912Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Jul 2013
- Primary completion
- Jun 2018
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 26
01
Overview
A Phase 3 trial of ACAM-CDIFF in Clostridium difficile infection (CDI), sponsored by Sanofi. Started Jul 2013; status: terminated.
02
Drugs
ACAM-CDIFF
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT01887912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01887912.